 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...189190191192193194195196197198199...203204» |
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Nov 6, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2019 --> Nov 2019
- || Humira (adalimumab) / AbbVie
Trial primary completion date, HEOR: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo (clinicaltrials.gov) - Nov 6, 2015
P=N/A, N=70, Recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2019 --> Nov 2019 Trial primary completion date: Aug 2016 --> Mar 2017
- |||| Tremfya (guselkumab) / J&J
Trial primary completion date: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Nov 1, 2015
P3, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2016 --> Mar 2017 Trial primary completion date: Sep 2015 --> May 2016
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Humira (adalimumab) / AbbVie
New P1/2 trial: DIPIT: Diabetes Islet Preservation Immune Treatment (clinicaltrials.gov) - Oct 26, 2015
P1/2, N=42, Not yet recruiting, Sponsor: Camillo Ricordi and Jay Skyler
- ||| remtolumab (ABT-122) / AbbVie
P2 data, Enrollment change: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Oct 23, 2015
P2, N=225, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Sep 2015 --> May 2016 N=160 --> 225
- ||| Humira (adalimumab) / Eisai, AbbVie
New trial, P4 data: Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination" (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=600, Recruiting, Sponsor: AbbVie
- || Remicade (infliximab) / J&J, Olumiant (baricitinib) / Incyte, Eli Lilly, Humira (adalimumab) / AbbVie
Trial primary completion date: PsoBest - The German Psoriasis Registry (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=3500, Recruiting, Sponsor: Universit
N=160 --> 225 Trial primary completion date: Dec 2016 --> Dec 2025
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: CALM: Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Oct 21, 2015
P3, N=253, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2016 --> Dec 2025 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease (clinicaltrials.gov) - Oct 10, 2015
P3, N=28, Completed, Sponsor: AbbVie
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| etrolizumab (RG7413) / Roche
Trial primary completion date: HIBISCUS II: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Oct 2, 2015
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Mar 2018
- |||| etrolizumab (RG7413) / Roche
Trial primary completion date: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Oct 2, 2015
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Nov 2017 --> Mar 2018
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (clinicaltrials.gov) - Sep 29, 2015
P4, N=110, Completed, Sponsor: University Hospital, Tours
Trial primary completion date: Nov 2017 --> Mar 2018 Active, not recruiting --> Completed
- ||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
New trial: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=950, Recruiting, Sponsor: Celltrion
- ||| Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
New trial: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=1000, Recruiting, Sponsor: Celltrion
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed, Monotherapy: Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) (clinicaltrials.gov) - Sep 10, 2015
P3, N=340, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
New trial: Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease (clinicaltrials.gov) - Sep 3, 2015
P=N/A, N=40, Recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- | Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - Aug 26, 2015
P3, N=10, Recruiting, Sponsor: AbbVie
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Immunomodulating: Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator (clinicaltrials.gov) - Aug 25, 2015
P=N/A, N=20, Recruiting, Sponsor: Indiana University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial termination, Trial primary completion date: SPARTA: Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis (clinicaltrials.gov) - Aug 20, 2015
P4, N=7, Terminated, Sponsor: Glostrup University Hospital, Copenhagen
Not yet recruiting --> Recruiting N=50 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> May 2012; It was not possible to recruit patients
- Humira (adalimumab) / Eisai, AbbVie
Biomarker, Trial completion, Trial primary completion date: Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis (clinicaltrials.gov) - Aug 20, 2015
P4, N=50, Completed, Sponsor: Glostrup University Hospital, Copenhagen
N=50 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> May 2012; It was not possible to recruit patients Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Dec 2013
- Humira (adalimumab) / Eisai, AbbVie
Biomarker, Trial completion, Trial primary completion date: Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=40, Completed, Sponsor: Glostrup University Hospital, Copenhagen
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Dec 2013 Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Jul 2013
- |||||| Humira (adalimumab) / AbbVie
Enrollment open: Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Aug 14, 2015
P3, N=200, Recruiting, Sponsor: AbbVie
Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Jul 2013 Not yet recruiting --> Recruiting
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: IMAgINE 2: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 (clinicaltrials.gov) - Aug 14, 2015
P3, N=100, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Apr 2018
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Special Investigation (Long-term Investigation) in Patients With Crohn's Disease (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Sep 2016 --> Apr 2018 Trial primary completion date: Mar 2017 --> May 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=100, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Mar 2017 --> May 2016 Trial primary completion date: Jun 2017 --> May 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jun 2017 --> May 2016 Trial primary completion date: May 2017 --> Dec 2017
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Trial initiation date, Trial primary completion date: Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=30, Recruiting, Sponsor: Northwestern University
Trial primary completion date: May 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Jul 2015 | Trial primary completion date: Dec 2015 --> Apr 2016
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: LOTOS: Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=5500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Jul 2015 | Trial primary completion date: Dec 2015 --> Apr 2016 N=3000 --> 5500
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: RADAR: A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis (clinicaltrials.gov) - Aug 13, 2015
P4, N=76, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=3000 --> 5500 Active, not recruiting --> Completed | N=320 --> 76
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=266, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | N=320 --> 76 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting N=80 --> 140
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Enrollment change, Trial primary completion date: ROCKIES: Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab (clinicaltrials.gov) - Aug 12, 2015
P4, N=90, Active, not recruiting, Sponsor: Amgen
N=80 --> 140 Recruiting --> Active, not recruiting | N=250 --> 90 | Trial primary completion date: Feb 2016 --> Jun 2015
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial termination, HEOR: Evaluation of Health Costs and Resource Utilization (clinicaltrials.gov) - Aug 11, 2015
P4, N=51, Terminated, Sponsor: University of Western Ontario, Canada
Recruiting --> Active, not recruiting | N=250 --> 90 | Trial primary completion date: Feb 2016 --> Jun 2015 N=160 --> 51 | Recruiting --> Terminated; recruitment issues
- Humira (adalimumab) / Eisai, AbbVie
New P1 trial: TAM-RT: A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers (clinicaltrials.gov) - Aug 6, 2015
P1, N=27, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- ||| Humira (adalimumab) / AbbVie
New trial, Patient reported outcomes: UCanADA: Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis (clinicaltrials.gov) - Jul 23, 2015
P=N/A, N=200, Enrolling by invitation, Sponsor: AbbVie
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 22, 2015
P3, N=60, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
N=160 --> 51 | Recruiting --> Terminated; recruitment issues Recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: VISUAL III: A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (clinicaltrials.gov) - Jul 21, 2015
P3, N=400, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Trial primary completion date: Mar 2017 --> Mar 2018
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2017 --> Mar 2018 Initiation date: Jun 2015 --> Oct 2015
- |||| Humira (adalimumab) / AbbVie
Trial primary completion date: Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jul 21, 2015
P3, N=300, Recruiting, Sponsor: AbbVie
Initiation date: Jun 2015 --> Oct 2015 Trial primary completion date: Jul 2015 --> Oct 2015
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=190, Recruiting, Sponsor: AbbVie
Trial primary completion date: Jul 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- ||| remtolumab (ABT-122) / AbbVie
Enrollment closed, P2 data, Trial primary completion date: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jul 20, 2015
P2, N=160, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date, Monotherapy: Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH) (clinicaltrials.gov) - Jul 17, 2015
P3, N=340, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015 Trial primary completion date: Jul 2016 --> Mar 2016
- ||| Humira (adalimumab) / Eisai, AbbVie
Biomarker, New trial: EUREKA: A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=200, Recruiting, Sponsor: AbbVie
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date: Efficacy Study of Adalimumab to Treat Interstitial Cystitis (clinicaltrials.gov) - Jul 16, 2015
P3, N=43, Completed, Sponsor: ICStudy, LLC
Trial primary completion date: Jul 2016 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jun 2013
- |||||||||| Humira (adalimumab) / AbbVie
New P3 trial: Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jul 16, 2015
P3, N=200, Not yet recruiting, Sponsor: AbbVie
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Jul 14, 2015
P3, N=200, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jun 2013 Trial primary completion date: Mar 2016 --> Oct 2017
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115 (clinicaltrials.gov) - Jul 14, 2015
P3, N=270, Enrolling by invitation, Sponsor: AbbVie
Trial primary completion date: Mar 2016 --> Oct 2017 Trial primary completion date: Aug 2016 --> Jan 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Special Investigation in Patients With Ulcerative Colitis (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=1500, Recruiting, Sponsor: AbbVie
Trial primary completion date: Aug 2016 --> Jan 2017 Trial primary completion date: Mar 2017 --> Dec 2017
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Trial primary completion date: Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI]) (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=130, Recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
- Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 14, 2015
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Nov 2016 Trial primary completion date: Jul 2015 --> Mar 2016